RxE2 Overview
RxE2 Inc specializes in decentralized clinical trials by integrating pharmacy practice into all aspects of the trial process. This approach allows local pharmacists to leverage their patient insights to enhance accessibility for participants, streamline trial operations, and reduce costs. By involving pharmacists as medication experts, RxE2 aims to provide more accurate data for study sponsors and improve the overall efficiency of clinical trials. in 2021, RxE2 established a local R&D center following the acquisition of Habitu, which integrated the activity of the Start-Up into the global company.
Latest News
growth-positive
RxE2 Agrees to Acquire Habitu to Form the First AI Driven, Pharmacist-Led, Clinical Trial Platform
RxE2 has agreed to acquire Habitu, an Israeli-based technology company that focuses on peoples habits and behaviors to create an AI-powered engine for analyzing patient data in clinical trials. The acquisition will enhance RxE2s pharmacist-led trial services and improve patient outcomes. Habitus technology platform will enable RxE2 to provide and manage pharmacist-led trial services in a distributed model, localizing the decentralized clinical trial model. The AI-powered engine can predict potential challenges and improve decision-making for pharmacists and medical teams. RxE2 aims to make decentralized clinical trials more accessible, reduce timelines and costs, and provide more accurate data.
Acquisition
Team Members
1
Employees: 1-10
Web & Social Links
| Website | www.rxe2.com/ |
Locations
Hod Hasharon, Israel
Fargo, ND, USA
Photos & Videos
No files yet
